Will the FDA approve Capricor’s deramiocel by November 22, 2026?

Question

This market will resolve YES if… the U.S. Food and Drug Administration grants full, accelerated, conditional or otherwise legally effective marketing approval to Capricor Therapeutics’ biologics license application for deramiocel (CAP-1002) for treatment of Duchenne muscular dystrophy on or before November 22, 2026 at 11:59:59 p.m. Eastern Time.

An FDA approval letter authorising commercial marketing for the indication under review will qualify.

Approval with post-marketing requirements, a nar

Problyx · Accepted Answer

No — the community forecast puts this at 76%.

Problyx · Answer

Yes — the community forecast puts this at 24%.